These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34018490)

  • 1. A pilot study of everolimus and radiation for neuroendocrine liver metastases.
    Myrehaug S; Chan DL; Rodriguez-Freixinos V; Chung H; Hallet J; Law C; Patel C; Milot L; Hudson J; Chen H; Singh S
    Endocr Relat Cancer; 2021 Jun; 28(8):541-548. PubMed ID: 34018490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic Contrast-enhanced CT to Evaluate Early Response in Neuroendocrine Liver Metastases Treated With Everolimus and Radiation.
    Hudson JM; Singh S; Milot L; Patel C; Bailey C; Rodriguez-Freixinos V; Chan D; Hallet J; Law C; Myrehaug S
    Anticancer Res; 2022 Jul; 42(7):3523-3527. PubMed ID: 35790284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases.
    Kim HS; Shaib WL; Zhang C; Nagaraju GP; Wu C; Alese OB; Chen Z; Brutcher E; Renfroe M; El-Rayes BF
    Cancer; 2018 May; 124(9):1992-2000. PubMed ID: 29451701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic Ablative Radiotherapy for the Management of Liver Metastases from Neuroendocrine Neoplasms: A Preliminary Study.
    Hudson JM; Chung HT; Chu W; Taggar A; Davis LE; Hallet J; Law CHL; Singh S; Myrehaug S
    Neuroendocrinology; 2022; 112(2):153-160. PubMed ID: 33530088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
    Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study.
    Braat AJAT; Bruijnen RCG; van Rooij R; Braat MNGJA; Wessels FJ; van Leeuwaarde RS; van Treijen MJC; de Herder WW; Hofland J; Tesselaar MET; de Jong HWAM; Lam MGEH
    Lancet Oncol; 2020 Apr; 21(4):561-570. PubMed ID: 32112737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study.
    Walter T; Lepage C; Coriat R; Barbier E; Cadiot G; Caroli-Bosc FX; Aparicio T; Bouhier-Leporrier K; Hentic-Dhome O; Gay F; Dupont-Gossart AC; Duluc M; Lepere C; Lecomte T; Smith D; Petorin C; Di-Fiore F; Ghiringhelli F; Legoux JL; Guimbaud R; Baudin E; Lombard-Bohas C; de Baère T;
    Eur J Cancer; 2019 Dec; 123():92-100. PubMed ID: 31678771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multimodal therapy with aggressive hepatectomy, everolimus, and octreotide for metastatic pancreatic neuroendocrine neoplasm enables 10-year survival.
    Yumoto S; Nakagawa S; Hayashi H; Ogawa D; Shiraishi Y; Sato H; Matsumoto T; Imai K; Yamashita YI; Baba H
    Clin J Gastroenterol; 2022 Dec; 15(6):1136-1144. PubMed ID: 36038805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CT perfusion in normal liver and liver metastases from neuroendocrine tumors treated with targeted antivascular agents.
    Ng CS; Wei W; Duran C; Ghosh P; Anderson EF; Chandler AG; Yao JC
    Abdom Radiol (NY); 2018 Jul; 43(7):1661-1669. PubMed ID: 29075824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (
    Lung MS; Hicks RJ; Pavlakis N; Link E; Jefford M; Thomson B; Wyld DK; Liauw W; Akhurst T; Kuru N; Michael M
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):150-157. PubMed ID: 32030887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Real-world Multicenter Prospective Study of Everolimus in Pancreatic Neuroendocrine Tumors: The 'PROTOR' Study.
    Kaltsas G; Andreadis C; Kosmidis P; Mavroudis D; Pazaitou-Panayiotou K; Vaslamatzis M; Athanasiadis I
    Anticancer Res; 2022 Apr; 42(4):1941-1948. PubMed ID: 35347014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry.
    Wong TY; Zhang KS; Gandhi RT; Collins ZS; O'Hara R; Wang EA; Vaheesan K; Matsuoka L; Sze DY; Kennedy AS; Brown DB
    BMC Cancer; 2022 Mar; 22(1):224. PubMed ID: 35232410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
    Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
    Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraarterial Peptide Receptor Radionuclide Therapy Using
    Lawhn-Heath C; Fidelman N; Chee B; Jivan S; Armstrong E; Zhang L; Lindsay S; Bergsland EK; Hope TA
    J Nucl Med; 2021 Feb; 62(2):221-227. PubMed ID: 32513903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments.
    Angelousi A; Kamp K; Kaltsatou M; O'Toole D; Kaltsas G; de Herder W
    Neuroendocrinology; 2017; 105(4):394-402. PubMed ID: 28122378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival.
    Mazzaglia PJ; Berber E; Milas M; Siperstein AE
    Surgery; 2007 Jul; 142(1):10-9. PubMed ID: 17629995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Everolimus in Extrapancreatic Neuroendocrine Tumor: A Comprehensive Review of Literature.
    Faggiano A; Malandrino P; Modica R; Agrimi D; Aversano M; Bassi V; Giordano EA; Guarnotta V; Logoluso FA; Messina E; Nicastro V; Nuzzo V; Sciaraffia M; Colao A
    Oncologist; 2016 Jul; 21(7):875-86. PubMed ID: 27053503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Y90 selective internal radiation therapy and peptide receptor radionuclide therapy for the treatment of metastatic neuroendocrine tumors: combination or not?
    Yilmaz E; Engin MN; Özkan ZG; Kovan B; Büyükkaya F; Poyanli A; Sağlam S; Başaran M; Türkmen C
    Nucl Med Commun; 2020 Dec; 41(12):1242-1249. PubMed ID: 32941405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
    Yao JC; Fazio N; Singh S; Buzzoni R; Carnaghi C; Wolin E; Tomasek J; Raderer M; Lahner H; Voi M; Pacaud LB; Rouyrre N; Sachs C; Valle JW; Fave GD; Van Cutsem E; Tesselaar M; Shimada Y; Oh DY; Strosberg J; Kulke MH; Pavel ME;
    Lancet; 2016 Mar; 387(10022):968-977. PubMed ID: 26703889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy.
    McStay MK; Maudgil D; Williams M; Tibballs JM; Watkinson AF; Caplin ME; Buscombe JR
    Radiology; 2005 Nov; 237(2):718-26. PubMed ID: 16192318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.